BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36375076)

  • 1. Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer.
    Arai M; Kosaka T; Yasumizu Y; Takeda T; Matsumoto K; Oya M
    Int J Urol; 2023 Feb; 30(2):235-239. PubMed ID: 36375076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
    Spiegel DY; Hong JC; Oyekunle T; Waters L; Lee WR; Salama JK; Koontz BF
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):834-842. PubMed ID: 30419308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
    Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
    J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
    Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
    Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.
    Nam W; Choi SY; Yoo SJ; Ryu J; Lee J; Kyung YS; Han JH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Investig Clin Urol; 2018 Jan; 59(1):18-24. PubMed ID: 29333510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer.
    Roy S; Grimes S; Eapen L; Spratt DE; Malone J; Craig J; Morgan SC; Malone S
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1179-1188. PubMed ID: 32565318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.
    Dai B; Qu YY; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Yang WY
    Asian J Androl; 2013 Jul; 15(4):466-70. PubMed ID: 23708460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT.
    Ayoub Z; Khader J; Bulbul M; Khauli RB; Andraos TY; Shamseddine A; Mukherji D; Geara FB
    BMC Urol; 2022 Dec; 22(1):204. PubMed ID: 36503556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer.
    Masuda H; Fujimoto A; Kanesaka M; Hou K; Suyama T; Araki K; Kojima S; Naya Y
    Anticancer Res; 2021 Sep; 41(9):4443-4446. PubMed ID: 34475067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Takei A; Sakamoto S; Wakai K; Tamura T; Imamura Y; Xu M; Maimaiti M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Int J Urol; 2018 Apr; 25(4):352-358. PubMed ID: 29323427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.
    Zapatero A; Álvarez A; Guerrero A; Maldonado X; González San Segundo C; Cabeza MA; Martín de Vidales C; Solé JM; Pedro Olivé A; Casas F; Boladeras A; Vázquez de la Torre ML; Vara S; Calvo FA
    Radiother Oncol; 2021 Jul; 160():115-119. PubMed ID: 33964325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score-matched analysis.
    Sutani S; Yorozu A; Toya K; Shiraishi Y; Nishiyama T; Yagi Y; Nakamura K; Saito S
    Brachytherapy; 2021; 20(1):10-18. PubMed ID: 33069598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased testosterone recovery after androgen deprivation therapy for prostate cancer.
    Long ME; Vitale AM; Mott SL; Tracy C; Garje R; Zakharia Y; Brown JA
    Can J Urol; 2021 Aug; 28(4):10738-10742. PubMed ID: 34378507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials.
    Nabid A; Carrier N; Vigneault E; Martin AG; Bahary JP; Van Nguyen T; Vavassis P; Vass S; Brassard MA; Bahoric B; Archambault R; Vincent F; Bettahar R; Duclos M; Wilke D; Souhami L
    Radiother Oncol; 2024 Jun; 195():110256. PubMed ID: 38552845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer.
    Nishiyama T
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):179-90. PubMed ID: 22269996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer.
    Guin S; Jun T; Patel VG; Ayers KL; Deitz M; Cai Y; Zhou X; Tsao CK; Oh WK; Chen R; Liaw BC
    JCO Clin Cancer Inform; 2022 Jun; 6():e2200010. PubMed ID: 35696627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
    BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.